Skip to main content
Sopharma AD logo

Sopharma AD — Investor Relations & Filings

Ticker · SFA ISIN · BG11SOSOBT18 LEI · 097900BGGW0000048796 BSOBGN Manufacturing
Open in API
Filings indexed 1,484 across all filing types
Latest filing 2023-06-09 Regulatory Filings
Country BG Bulgaria
Listing BSOBGN SFA

About Sopharma AD

https://www.sopharmagroup.com/

Sopharma AD is a pharmaceutical company founded in 1933 that specializes in the production, distribution, and export of a wide range of medical products. The company's portfolio includes prescription (Rx) and over-the-counter (OTC) medicines, encompassing both branded and generic drugs. A key area of focus is its traditional plant-based products. Sopharma develops treatments for various conditions, including liver disease, pain management, and smoking cessation. Operating from EU-GMP certified facilities, the company also provides contract manufacturing services and has an established presence in over 40 international markets.

Recent filings

Filing Released Lang Actions
A transaction concluded by the subsidiary "Pharmalogistika" AD under Art. 114, para. 3 of the Law on Public Offering of Securities requiring prior approval of the public company
Regulatory Filings Classification · 95% confidence The document is titled "Current report №44/ 2023" and details a specific transaction (a lease agreement) concluded by a subsidiary, which involves interested parties (members of the Board of Directors serving on both involved entities). It explicitly references articles from the Securities Act concerning transactions involving interested parties and sets out the value and applicability of certain legal provisions. This structure strongly suggests a mandatory regulatory disclosure concerning related-party transactions or significant corporate events, rather than a general financial report (like 10-K or IR) or a simple announcement of a report (like RPA). Since it is a specific, mandatory disclosure that doesn't fit the highly specific categories like DIRS (Director's Dealing) or DIV (Dividend Notice), it falls best under the general regulatory filing category, RNS, which serves as a fallback for miscellaneous mandatory disclosures not covered elsewhere.
2023-06-09 English
Notification from "Donev investments holding" AD under Art. 19 of Regulation (EU) No 596/2014 of 7 June 2023.
Director's Dealing Classification · 100% confidence The document is explicitly titled "NOTIFICATION OF INSIDERS' TRANSACTIONS under art. 19 of Regulation 596/2014". It details transactions (Buy operations) executed by an insider ("Donev Investments Holding" AD related to Ognian Donev) involving company warrants, including dates, quantities, and prices. This directly corresponds to the definition of Director's Dealing (insider trades). Filing Category: Director's Dealing (Code: DIRS).
2023-06-09 English
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of 7 June 2023.
Director's Dealing Classification · 100% confidence The document explicitly states it is a "NOTIFICATION OF INSIDERS' TRANSACTIONS under art. 19 of Regulation 596/2014". It details transactions executed by Mr. Ognian Donev, the Chairman of the Board of Directors, involving the sale of company warrants. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The appropriate code is DIRS.
2023-06-09 English
Notification from Ognian Donev under Art. 19 of Regulation (EU) No 596/2014 of 8 June 2023.
Director's Dealing Classification · 100% confidence The document is explicitly titled 'NOTIFICATION OF INSIDERS' TRANSACTIONS under art. 19 of Regulation 596/2014'. It details specific transactions (Sell operations) involving warrants executed by Mr. Ognian Donev, who is the Chairman of the Board of Directors. This directly corresponds to the definition of Director's Dealing (insider trades by directors/executives). The appropriate code is DIRS.
2023-06-09 English
SFA_2022_ind_Financial_Report_according_to_BFSC_standards_BG.xls
Regulatory Filings Classification · 19% confidence
2023-06-07 Bulgarian
097900BGGW0000048796-20221231-BG-SEP.xhtml
Annual Report Classification · 100% confidence The document is a comprehensive annual financial report for 'Sopharma AD' for the year 2022. It includes detailed financial statements (Statement of Comprehensive Income, Statement of Financial Position, Cash Flow Statement, Statement of Changes in Equity), explanatory notes, management reports, and an auditor's report. Since it covers the full fiscal year and contains substantive financial data, it is classified as an Annual Report (10-K equivalent). FY 2022
2023-06-07 Bulgarian

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.